- Revenues for the 4th quarter 2023 was 5.4 MSEK (4th quarter 2022: 3.2 MSEK) and for the total year 16.8 MSEK (2022: 15.3 MSEK)
- Cash position on
December 31, 2023 , was 31.0 MSEK (2022: 111.7 MSEK)
The figures above are preliminary and unaudited and are being released in view of the upcoming rights issue. The year-end report for 2023 will as earlier communicated be announced on
- On
January 16, 2024 , the extraordinary general meeting resolved to approve the board of director’s resolution fromDecember 14, 2023 , to conduct a rights issue of units of up to approximately 140.9 MSEK - The rights issue is covered by subscription undertakings and by guarantee commitments totaling about 84 MSEK, which together with existing financial resources will secure funding of the company’s activities for at least 12 months. Among the parties providing the subscription undertakings are senior management and all the members of the board of directors, including Thomas Feldthus CEO, with
SEK 0.75 million and Jørgen Drejer, chairman of the board of directors, withSEK 0.4 million
Comment from CEO
“Our focus during 2023 was two-fold; to keep establishing productive commercial collaborations through our business development efforts and, at the same time, progressing our portfolio by leveraging Saniona’s expertise in the field of ion-channel drug discovery to identify and propel additional selective ion channel clinical candidates in a range of epilepsy indications and beyond. I am proud of the significant advancements we made during the year, in particular on our epilepsy pipeline.
During the fourth quarter, we selected two clinical candidates: SAN2355 for epilepsy and SAN2465 for major depressive disorder (MDD). The selection of SAN2355 as the first clinical candidate from our Kv7 epilepsy program marks a significant epilepsy pipeline milestone as Kv7 activation, based on the existing clinical experience represents a validated mechanism of action to control seizures. SAN2355 could represent a promising new generation of subtype selective, effective and well-tolerated anti-seizure medication. The selection of SAN2465 as a clinical candidate for MDD follows encouraging results which positions SAN2465 as an innovative and rapid-acting approach to treating MDD and its associated comorbidities. Development of rapid-acting treatments for depression has been a major hurdle for the pharmaceutical industry during the past decades, so we see a huge commercial potential for SAN2465.
Earlier in the year, we partnered with AstronauTx on Alzheimer’s research, potentially earning up to
Medix, our Mexican partner, is optimistic about tesofensine’s potential approval as a new obesity treatment in
Our research platform has demonstrated significant potential in creating innovative treatment candidates for a range of neurological and psychiatric diseases. With a track record of successful partnerships, we're poised for further engagements. Confident in ongoing discussions, I anticipate securing additional partnerships this year. Moving ahead, we will intensify our initiatives to discover, develop and deliver innovative treatments to patients worldwide. I look forward to providing further updates on our progress.”
© Modular Finance, source